# Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

> **NCT02231749** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1390 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT02231749
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-16
- **Primary completion:** 2017-06-26
- **Final completion:** 2025-03-21
- **Target enrollment:** 1390 (ACTUAL)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231749, "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02231749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*